Halozyme to Update Financial Guidance and Share Business Outlook
Event summary
- Halozyme will host an investor call on January 28, 2026, to discuss preliminary 2025 revenue results and updated 2026-2028 financial guidance.
- CEO Dr. Helen Torley and CFO Nicole LaBrosse will provide a business update during the call.
- Halozyme's ENHANZE® technology has been licensed to over 15 leading pharmaceutical and biotechnology companies.
- The company is expanding its drug delivery technology portfolio with Hypercon™, licensed to partners including Johnson & Johnson and Eli Lilly.
The big picture
Halozyme's investor call comes at a critical juncture as the company looks to solidify its position in the drug delivery technology space. With ENHANZE® already integrated into over one million patient treatments and Hypercon™ expanding its portfolio, the updated financial guidance will be closely watched by investors to gauge the company's growth trajectory and strategic direction in a competitive biopharmaceutical landscape.
What we're watching
- Revenue Trajectory
- How preliminary 2025 revenue results compare to previous guidance and market expectations.
- Technology Expansion
- The pace at which Hypercon™ technology adoption will impact Halozyme's partnership portfolio and revenue streams.
- Market Positioning
- Whether Halozyme can sustain its competitive edge in drug delivery technology amid increasing industry collaboration.